Solabegron
CAS: 252920-94-8
Ref. 3D-CKA92094
| 1mg | A consultar | ||
| 2mg | A consultar | ||
| 5mg | A consultar | ||
| 10mg | A consultar | ||
| 25mg | A consultar |
Información del producto
- (-)-(R)-3′-[[2-[[2-(3-Chlorophenyl)-2-hydroxyethyl]amino]ethyl]amino]biphenyl-3-carboxylic acid
- 3′-[[2-[[(2R)-2-(3-Chlorophenyl)-2-hydroxyethyl]amino]ethyl]amino][1,1′-biphenyl]-3-carboxylic acid
- Gw 427353
- [1,1′-Biphenyl]-3-carboxylic acid, 3′-[[2-[[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]ethyl]amino]-
Solabegron is a drug that has clinical relevance for the treatment of bladder disorders. It is an agonist of the beta-3 adrenergic receptor, with no affinity for beta-1 or beta-2 receptors. In animal models, solabegron has been shown to increase detrusor muscle contractility and reduce urinary symptoms. Solabegron also acts as an inhibitor of DPP-IV, which is involved in the breakdown of glucagon-like peptide (GLP). The drug reduces body mass index and improves metabolic disorders in animals by stimulating GLP secretion. Solabegron is metabolized by CYP3A4 and has hydrogen bonding interactions with drugs such as erythromycin, clarithromycin, and telithromycin.
Propiedades químicas
Consulta técnica sobre: 3D-CKA92094 Solabegron
Si desea solicitar un presupuesto o realizar un pedido, por favor añada los productos deseados a su carrito y solicite un presupuesto o pedido desde el carrito. Es más rápido, más barato, y podrá beneficiarse de los descuentos y las ventajas disponibles.
